Aminolevulinic acid - DUSA

Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator PARTEQ Innovations
  • Developer DUSA Pharmaceuticals
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Brain cancer
  • Suspended Warts
  • No development reported Barrett's oesophagus
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis; Skin cancer

Most Recent Events

  • 24 Jan 2017 DUSA Pharmaceuticals plans a phase III trial for Actinic keratosis in USA (NCT03024060)
  • 12 Sep 2016 DUSA Pharmaceuticals completes a phase II trial in Actinic keratosis in USA (Topical) (NCT02632110)
  • 01 Sep 2016 DUSA Pharmaceuticals completes a phase II trial for Actinic keratosis in USA (NCT02239679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top